QQ客服 官方微博 反馈留言

	Comparison of efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy analyzing multi-factor mediated disease-causing modules
	Gao, Hong[1]; Duan, Yuhong[2]; Fu, Xiaoxu[1]; Xie, Hongyan[1]; Liu, Ya[1]; Yuan, Haipo[1]; Zhou, Mingyang[1]; Xie, Chunguang[1]
	2018
卷号	13期号:12
URL标识	查看原文
WOS记录号	WOS:000452307600017
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4724601
专题	成都中医药大学
作者单位	1.[1]Chengdu Univ Tradit Chinese Med, Teaching Hosp, Sch Clin Med, Chengdu, Sichuan, Peoples R China 2.[2]Shaanxi Univ Tradit Chinese Med, Teaching Hosp, Dept Two Endocrinol, Xianyang, Peoples R China
推荐引用方式 GB/T 7714	Gao, Hong[1],Duan, Yuhong[2],Fu, Xiaoxu[1],et al. Comparison of efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy analyzing multi-factor mediated disease-causing modules[J],2018,13(12).
APA	Gao, Hong[1].,Duan, Yuhong[2].,Fu, Xiaoxu[1].,Xie, Hongyan[1].,Liu, Ya[1].,...&Xie, Chunguang[1].(2018).Comparison of efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy analyzing multi-factor mediated disease-causing modules.,13(12).
MLA	Gao, Hong[1],et al."Comparison of efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy analyzing multi-factor mediated disease-causing modules".13.12(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。